Author:
Langbour Camille,Rene Jessica,Goupille Philippe,Carvajal Alegria Guillermo
Publisher
Springer Science and Business Media LLC
Reference51 articles.
1. Ytterberg SR, Bhatt DL, Mikuls TR, Koch GG, Fleischmann R, Rivas JL, et al. Cardiovascular and cancer risk with tofacitinib in rheumatoid arthritis. N Engl J Med. 2022;386:316–26.
2. Traves PG, Murray B, Campigotto F, Galien R, Meng A, Di Paolo JA. JAK selectivity and the implications for clinical inhibition of pharmacodynamic cytokine signalling by filgotinib, upadacitinib, tofacitinib and baricitinib. Ann Rheum Dis. 2021;80:865–75.
3. Khosrow-Khavar F, Kim SC, Lee H, Lee SB, Desai RJ. Tofacitinib and risk of cardiovascular outcomes: results from the safety of tofacitinib in Routine care patients with rheumatoid arthritis (STAR-RA) study. Ann Rheum Dis. 2022;81:798–804.
4. Dougados M, Charles-Schoeman C, Szekanecz Z, Giles JT, Ytterberg SR, Bhatt DL, et al. Op0264 impact of baseline cardiovascular risk on the incidence of major adverse cardiovascular events in the tofacitinib rheumatoid arthritis clinical programme. In: Annals of the rheumatic diseases, vol. 81. BMJ Publishing Group Ltd; 2022. p. 175–6.
5. Fleischmann R, Kremer J, Cush J, Schulze-Koops H, Connell CA, Bradley JD, et al. Placebo-controlled trial of tofacitinib monotherapy in rheumatoid arthritis. N Engl J Med. 2012;367:495–507.
Cited by
7 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献